InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,691.41
(
-0.39%
)
US TECH 100
19,267.60
(
-0.35%
)
Dow Jones
41,934.28
(
-0.22%
)
Brent Oil
73.68
(
-0.87%
)
Bitcoin
62,666.22
(
-0.45%
)
Post# of 253160
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120470
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 210857

Tuesday, 01/16/2018 1:38:13 PM

Tuesday, January 16, 2018 1:38:13 PM

Post# of 253160
TNG.PA* starts phase-2 trial of TG4010 cancer vaccine in combination with Opdivo and chemotherapy in first-line, non-squamous NSCLC patients with low (or no) PD-L1 expression:

https://finance.yahoo.com/news/first-patient-dosed-phase-2-164500269.html

BMY is a co-sponsor of this single-arm trial, furnishing the Opdivo. The ct.g listing is at: https://clinicaltrials.gov/ct2/show/NCT03353675 .

*Since this trial was announced in Apr 2017, Transgene changed its ticker symbol from TRNG.PA to TNG.PA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up